摘要
目的:研究抗结核药(HRZ)与阿托伐他汀联用致肝损伤的特征及其机制。方法:随机把入选动物分为4组(空白对照组、HRZ组、阿托伐他汀组和阿托伐他汀+HRZ组),分别给予相应药物灌胃给药后于第10天、第35天及第55天检测并观察其肝功能指标、HE染色、CYP3A4和CYP2E1免疫组化染色以及CYP2E1原位杂交表达情况。结果:除空白对照组外,用药组均有肝损伤的发生,并与投药时间具有相关性,但阿托伐他汀+HRZ组(联用组)较单一用药组肝损伤程度更为严重。结论:这两类药物联合治疗于同一个体时,应慎重权衡药物性肝损伤的因素,在联合应用时应检测肝功能相关指标及肝活检的时间位点,推测肝功能损伤的加重可能与这两类药物联用后诱导CYP3A4和CYP2E1的表达有关。
Objective： To study the characteristics and mechanisms of liver function impaired in using anti-tubercu- lotic（HRZ） combined with atorvastatin. Methods： The randomly selected animals were divided into four groups： the blank control group, HRZ group, atorvastatin group and atorvastatin＋HRZ group. They were given the appropriate drugs administered orally, and in 10th day, 35th day and 55th day detecting and observing the liver function, HE stain- ing, CYP3A4 and CYP2EI immunohistochemistry and in situ hybridization expression of CYP2EI Happening. Results： In addition to the blank control group, in each treatment group liver injury with administration was time-dependent, but the combined treatment group was more serious than the drug alone group, in the degree of liver damage. Conclusion： For these two types of combination drug therapy in the same individual, people should carefully weigh the factors of drug-induced liver injury： should be examined liver function and liver biopsy time related indicators site; It is suggested that increased liver dysfunction may be associated with using these two types of the drug combination which induced CYP3A4 and CYP2EI.
出处
《抗感染药学》
2016年第5期978-985,共8页
Anti-infection Pharmacy
基金
昆明市卫计委基金课题(编号:20150103)
